XVR013m, a broadly-neutralizing VHH-Fc antibody targeting the S2 subunit of the SARS-CoV-2 spike with exceptional potency

XVR013m, a broadly-neutralizing VHH-Fc antibody targeting the S2 subunit of the SARS-CoV-2 spike with exceptional potency
• More than 7 million people have died from COVID-19 to date and SARS-CoV-2 continues to cause substantial disease around the world. High-risk
patients like immunocompromised and elderly are often not able to elicit adequate immune responses to vaccination and benefit from an
additional layer of protection in the form of complementary antibody therapy
1-5
• Monoclonal antibodies act immediately and can provide immune support for months. However, all previously/currently authorized antibodies
target the S1 subunit of the spike protein, a hotspot for mutations and emergence of new variants. All except one have completely lost their
neutralization potency against the currently circulating variants, leaving a vast unmet medical need
• Here we describe XVR013m, a monospecific bivalent VHH-Fc antibody containing: (i) the VHH R3DC23m, and (ii) an active human IgG1 Fc with
mutations for half-life extension, displaying exceptional breadth of neutralization and potency